The shareholder's call comes after Novartis experienced back-to-back setbacks in Phase 3 drug trials, a situation that directly impacts the SMI-listed heavyweight Novartis, combining material clinical trial failures with activist shareholder pressure for governance reform.
Major Novartis shareholder calls for board shake-up following back-to-back Phase 3 drug trial setbacks
A major shareholder of Novartis has urged a board overhaul after the company suffered consecutive failures in Phase 3 clinical trials.
SL
Sophie Laurent · FX & Rates Desk · 20 Sept 2026 · 00:23 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
SL
Written by
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
